Mustafa ÖZBEK, Erman ÇAKAL, Murat ÇALAPKULU, Hayri BOSTAN, İlknur ÖZTÜRK ÜNSAL, Sema HEPŞEN, Muhammed Erkam SENCAR

The visceral adiposity index, lipid accumulation product, and plasma atherogenic index are associated with subclinical atherosclerosis in patients with newly diagnosed acromegaly

Background /aim: Acromegaly is a rare chronic endocrine disorder, the active form of which is associated with an increased risk of cardiovascular and metabolic disease. Therefore, early diagnosis and treatment of cardiovascular diseases in acromegaly patients are important in terms of morbidity and mortality. The aim of this study was to determine whether the visceral adiposity index (VAI), lipid accumulation product (LAP), and plasma atherogenic index (PAI) are early cardiovascular risk markers in patients with active acromegaly. Materials and methods: The study included 45 patients newly diagnosed with acromegaly and 45 age–sex matched healthy control subjects. The VAI, LAP, and PAI values were calculated, and carotid artery intima media thickness (CIMT) was measured in both the patients and control groups. Results: The PAI, VAI, LAP, and CIMT values were significantly higher in patients with acromegaly compared with the control subjects (p < 0.004, p < 0.027, p

PDF

___

1. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocrine Reviews 2019; 40(1): 268-332. doi: 10.1210/er.2018-00115
2. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009; 119(11): 3189-3202. doi: 10.1172/ JCI39375
3. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009; 30(2): 152-177. doi: 10.1210/er.2008-0027
4. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.Trends in Endocrinology & Metabolism 2016; 27(7): 470-483. doi: 10.1016/j.tem.2016.04.014
5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews 2004; 25(1): 102–152. doi: 10.1210/er.2002-0022
6. Dogansen SC, Yalin GY, Tanrikulu S, Yarman S. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Hormone Metabolism Research 2018; 50: 408- 413. doi: 10.1055/a-0594-2404
7. Mercado M,Ramírez-Rentería C. Metabolic complications of acromegaly. Frontiers Hormone Research 2018; 49: 20-28. doi: 10.1159/000486001
8. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S et al.Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33(4): 920-922. doi: 10.2337/dc09-1825
9. A. Ciresi, M. C. Amato, G. Pizzolanti, C. Giordano Galluzzo. Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism 2012; 97(8): 2907–2915. doi: 10.1210/jc.2012-1518
10. A. Ciresi, M. C. Amato, R. Pivonello, E. Nazzari, L. F. Grasso et al. The Metabolic Profile in Active Acromegaly is GenderSpecific. Journal of Clinical Endocrinology and Metabolism 2013; 98(1): E51-E59. doi: 10.1210/jc.2012-2896
11. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovascular Disorders 2005; 8(5): 26 doi: 10.1186/1471-2261-5-26
12. Vieira JN, Braz MAD, Gomes FO, Silva PRD, Santos OTM et al. Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a crosssectional study. Sao Paulo Medical Journal 2019; 137(2): 126- 131. doi: 10.1590/1516-3180.2018.0293240119
13. Dobiasova M.AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 2006; 52(1): 64-71.
14. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical Journal of the Islamic Republic of Iran 2015; 25: 29. 240.
15. Onat A, Can G, Kaya H, Hergenç G.”Atherogenic index of plasma” (log10 triglyceride/high-density lipoproteincholesterol) predicts high blood pressure, diabetes, and vascular events. Journal of Clinical Lipidology 2010; 4(2): 89- 98. doi: 10.1016/j.jacl.2010.02.005
16. Cansu GB, Yılmaz N, Yanıkoğlu A, Ozdem S, Belgi Yıldırım A et al. Assessment of Diastolic Dysfunction, Arterial Stiffness, and Carotid Intima-Media Thickness in Patients with Acromegaly. Endocrine Practice 2017; 23(5): 536545. doi:10.4158/EP16163. OR
17. Katznelson L, Laws ER, Melmed S, Molitch ME, and Murad MH. Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2014; 10: 3933-3951. doi: 10.1210/jc.2014-2700
18. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM. Growth hormone and pituitary radiotherapy, but notserum insulin-like growth factor-concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004; 89 (4): 1613-1617. doi: 10.1210/jc.2003-031584
19. Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eurepean Journal of Endocrinology 2011; 165(5): 713-721. doi: 10.1530/EJE-11-0408
20. Kirilov G, Zacharieva S, Alexandrov AS, Lozanov V, Mitev V. Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine. Methods and Findings in Experimental and Clinical Pharmacology 2009; 31(7): 457-461.doi: 10.1358/mf.2009.31.7.1406701
21. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Disease 2011; 27(5): 10:88. doi: 10.1186/1476-511X-10-88
22. Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS et al. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 2012; 15(4): 539-551. doi: 10.1007/s11102-011-0365-5
23. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Disease 2011; 19(10): 183. doi: 10.1186/1476-511X-10-183
24. Kahn HS: The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006; 29: 151–153. doi: 10.2337/ diacare.29.1.151
25. Kahn HS: The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. Diabetes Care. BMC Cardiovascular Disorders 2005; 8(5): 26. doi: 10.1186/1471- 2261-5-26
26. Shin KA, Kim YJ. Usefulness Of Surrogate Markers Of Body Fat Distribution For Predicting Metabolic Syndrome In Middle-Aged And Older Korean Populations. Diabetes Metab Syndr Obes 2019; 1(12): 2251-2259. doi: 10.2147/ DMSO.S217628
27. Goliasch G, Wiesbauer F, Blessberger H, Demyanets S, Wojta J et al. Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. Jounal of Clinical Lipidology 2015; 9: 801–806. doi: 10.1016/j.jacl.2015.08.009
28. Wiecek M, Szymura J, Sproull J, Szygula Z. Decreased Blood Asprosin in Hyperglycemic Menopausal Women as a Result of Whole-Body Cryotherapy Regardless of Metabolic Syndrome. Journal of Clinical Medicine 2019; 8(9): 1428.doi: 10.3390/jcm8091428
29. Shen S, Lu Y, Dang Y, Qi H, Shen Z et al. Effect of aerobic exercise on the atherogenicindex of plasma in middle-aged Chinese men with various body weights. International Journal of Cardiology 2017; 230: 1–5. doi: 10.1016/j. ijcard.2016.12.132
30. Zhu XW, Deng FY, Lei SF. Meta-analysis of atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Primary Care Diabetes 2015; 9: 60–67. doi: 10.1016/j.pcd.2014.03.007
31. Cai G, Shi G, Xue S, Lu W.The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine (Baltimore) 2017; 96(37): e8058.
32. Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Disease 2018; 17(1): 197. doi: 10.1186/s12944-018-0828-z
33. Cai G, Liu W, Lv S, Wang X, Guo Y et al. Gender-specific associations between atherogenic index of plasma and the presence and severity of acute coronary syndrome in very young adults: a hospital based observational study. Lipids Health Disease 2019; 18(1): 99. doi: 10.1186/s12944-019-1043-2
34. Guo Q, Zhou S, Feng X, Yang J, Qiao J et al. The sensibility of the new blood lipid indicator--atherogenic index of plasma (AIP) in menopausal women with coronary artery disease. Lipids Health Disease 2020; 19(1): 27. doi: 10.1186/s12944- 020-01208-8
35. Balta S, Aparci M, Ozturk C, Yildirim AO, Demir M et al. Carotid intima media thickness and subclinical early atherosclerosis. International Journal of Cardiology 2016; 203: 1146. doi: 10.1016/j.ijcard.2015.11.025
36. Kucuk A, Uslu AU, Arslan S, Balta S, Ozturk C et al. IschemiaModified Albumin and Atherosclerosis in Patients With Familial Mediterranean Fever. Angiology 2016; 67: 456–460. doi: 10.1177/0003319715595744
37. Uslu AU, Kucuk A, Balta S, Ozturk C, Arslan S et al. The relation between ischemia modified albumin levels and carotid intima media thickness in patients with rheumatoid arthritis. International Journal of Rheumaologic Disease 2019; 22(1): 32-37. doi: 10.1111/1756-185X.12851
38. Topsakal S, Akin F, Turgut S, Yaylali GF, Herek D et al. Relationship of apelin, procalcitonin, and fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann Clinical Biochemisty 2015; 52(Pt4): 456461. doi: 10.1177/0004563214562431